These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 32415802

  • 41. Novel Trial Design: CHIEF-HF.
    Spertus JA, Birmingham MC, Butler J, Lingvay I, Lanfear DE, Abbate A, Kosiborod ML, Fawcett C, Burton P, Damaraju CV, Januzzi JL, Whang J.
    Circ Heart Fail; 2021 Mar; 14(3):e007767. PubMed ID: 33724883
    [Abstract] [Full Text] [Related]

  • 42. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Lavalle-González FJ, Eliaschewitz FG, Cerdas S, Chacon Mdel P, Tong C, Alba M.
    Curr Med Res Opin; 2016 Mar; 32(3):427-39. PubMed ID: 26579834
    [Abstract] [Full Text] [Related]

  • 43. Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction.
    Salvioni E, Corrà U, Piepoli M, Rovai S, Correale M, Paolillo S, Pasquali M, Magrì D, Vitale G, Fusini L, Mapelli M, Vignati C, Lagioia R, Raimondo R, Sinagra G, Boggio F, Cangiano L, Gallo G, Magini A, Contini M, Palermo P, Apostolo A, Pezzuto B, Bonomi A, Scardovi AB, Filardi PP, Limongelli G, Metra M, Scrutinio D, Emdin M, Piccioli L, Lombardi C, Cattadori G, Parati G, Caravita S, Re F, Cicoira M, Frigerio M, Clemenza F, Bussotti M, Battaia E, Guazzi M, Bandera F, Badagliacca R, Di Lenarda A, Pacileo G, Passino C, Sciomer S, Ambrosio G, Agostoni P, MECKI score research group.
    ESC Heart Fail; 2020 Feb; 7(1):371-380. PubMed ID: 31893579
    [Abstract] [Full Text] [Related]

  • 44. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Nassif ME, Windsor SL, Tang F, Khariton Y, Husain M, Inzucchi SE, McGuire DK, Pitt B, Scirica BM, Austin B, Drazner MH, Fong MW, Givertz MM, Gordon RA, Jermyn R, Katz SD, Lamba S, Lanfear DE, LaRue SJ, Lindenfeld J, Malone M, Margulies K, Mentz RJ, Mutharasan RK, Pursley M, Umpierrez G, Kosiborod M.
    Circulation; 2019 Oct 29; 140(18):1463-1476. PubMed ID: 31524498
    [Abstract] [Full Text] [Related]

  • 45. Captopril reduces the VE/VCO2 ratio in myocardial infarction patients with low ejection fraction.
    McConnell TR, Menapace FJ, Hartley LH, Pfeffer MA.
    Chest; 1998 Nov 29; 114(5):1289-94. PubMed ID: 9824003
    [Abstract] [Full Text] [Related]

  • 46. Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO2 Slope in Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Hypertension.
    Klaassen SHC, Liu LCY, Hummel YM, Damman K, van der Meer P, Voors AA, Hoendermis ES, van Veldhuisen DJ.
    J Card Fail; 2017 Nov 29; 23(11):777-782. PubMed ID: 28736291
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.
    Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.
    J Med Econ; 2015 Feb 29; 18(2):113-25. PubMed ID: 25350645
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR, CANVAS Program Collaborative Group.
    Circulation; 2018 Jan 23; 137(4):323-334. PubMed ID: 29133604
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes.
    Nandula SR, Kundu N, Awal HB, Brichacek B, Fakhri M, Aimalla N, Elzarki A, Amdur RL, Sen S.
    Cardiovasc Diabetol; 2021 Feb 13; 20(1):44. PubMed ID: 33581737
    [Abstract] [Full Text] [Related]

  • 56. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.
    Wysham CH, Lefebvre P, Pilon D, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Duh MS, Ingham M.
    J Diabetes Complications; 2019 Feb 13; 33(2):140-147. PubMed ID: 30554838
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction.
    Omar M, Jensen J, Frederiksen PH, Kistorp C, Videbæk L, Poulsen MK, Möller S, Ali M, Gustafsson F, Køber L, Borlaug BA, Schou M, Møller JE.
    J Am Coll Cardiol; 2020 Dec 08; 76(23):2740-2751. PubMed ID: 33272368
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
    Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V.
    Circulation; 2019 Aug 27; 140(9):739-750. PubMed ID: 31291786
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.